La Jolla Pharmaceutical won FDA approval Thursday for Giapreza, a drug that treats dangerously low blood pressure in adults with septic or other distributive shock. Here are three things to know. 1.
SAN DIEGO, June 25, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to ...
The U.S. Food and Drug Administration today approved Giapreza (angiotensin II) injection for intravenous infusion to increase blood pressure in adults with septic or other distributive shock. "Shock, ...
Septic shock is the most severe complication of sepsis, which is a reaction to an infection. A person with sepsis may go into septic shock, which can cause organ failure and other life threatening ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback